ArticleMikrochimica acta2026
AI-driven lateral flow immunoassay for point-of-care detection of cardiac biomarkers in acute myocardial infarction.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A functionalized gold nanoparticle-based lateral flow immunoassay (AuNPs-LFIA) platform integrated with a deep learning-based machine vision model for the rapid and quantitative detection of cardiac biomarkers, myoglobin (Myo) and cardiac troponin I (cTnI). AuNPs@Ab probes with high specificity and stability were prepared. AuNPs were synthesized via the citrate reduction method, functionalized with HS-PEG-COOH, and covalently conjugated to antibodies through EDC/NHS-mediated coupling to yield high specificity and stability. Using this platform, the machine vision-assisted AuNPs-LFIA achieved detection limits of 0.224 ng/mL for Myo and 0.071 ng/mL for cTnI. Quantitative readouts were obtained within 8 min, representing a 46.7% improvement in detection efficiency compared to conventional methods. Analysis of spiked serum samples demonstrated a significant correlation with commercial assay kits (R² > 0.99), further validating the platform’s accuracy and clinical applicability. Overall, this AI-enhanced AuNPs-LFIA platform offers sensitive, rapid, and user-friendly quantification. Its robust scalability provides a practical strategy for point-of-care testing (POCT) in cardiovascular diagnostics, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.